Eikon Therapeutics has raised $381 million from its IPO, at the top end of its expectations, in another sign of a pickup in appetite for new biotech listings on the Nasdaq. The South San Francisco ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Eikon Therapeutics increased the ...

Feb 5 (Reuters) - Drug developer Eikon Therapeutics , headed by Merck veteran Roger Perlmutter, was valued at about $860.3 million after its shares opened 5.3% below their offer price in their Nasdaq ...

Despite progress made in cancer immunotherapy, some patients don’t respond to these treatments or they stop responding after a period of time. Eikon Therapeutics’ lead drug candidate could address ...

Eikon Therapeutics, Inc. (Nasdaq: EIKN), a California-based, late-stage biotechnology company, visits the Nasdaq MarketSite in Times Square. Eikon is led by executive and clinical teams behind the ...

Shares of Eikon Therapeutics are set to begin trading Thursday after the clinical-stage biopharmaceutical company's upsized initial public offering was priced at the top of expectations. Eikon late ...

Eikon Therapeutics raised an upsized US$381m late Wednesday from its Nasdaq IPO that included participation by Merck, a banker involved in the offering told IFR. The banks were multiple times ...

Eikon Therapeutics, Inc. (EIKN) announced the pricing of its upsized initial public offering of 21,177,600 shares of common stock at $18.00 per share. The biopharmaceutical company granted ...

These are the ceremonies for February 2026. Market opening and closing ceremonies take place on weekdays at the Nasdaq MarketSite Studio in Times Square and around the globe. Eikon Therapeutics, Inc. ...

Oncology-focused Eikon Therapeutics Inc. set the terms of its IPO Jan. 28, selling 17.648 million shares at a price range between $16 to $18 per share. At the top of the range, the Millbrae, ...

Eikon ‍Therapeutics (EIKN), a cancer drug developer led by Merck (MRK) veteran Roger Perlmutter, has filed for its U.S. IPO seeking a valuation of up to $908M with roughly 17.6M shares on offer. The ...